• AcelRx Pharmaceuticals Inc., of Redwood City, Calif., said it priced its underwritten public offering of 12.5 million shares of its common stock at $3.31 per share. Gross proceeds from the offering are expected to be approximately $41.38 million. AcelRx has granted the underwriters a 30-day option to purchase up to an aggregate of 1.875 million additional shares of common stock.

• Arrowhead Research Corp., of Pasadena, Calif., said it priced a public offering of approximately 1.8 million units at $2.26 per unit. Each unit consists of one share of common stock and one warrant to purchase 0.50 of a share of common stock. The sale of the units is expected to close Dec. 12.

• Northwest Biotherapeutics Inc., of Bethesda, Md., said it priced an underwritten public offering of 3 million shares of common stock, and warrants to purchase up to an aggregate 1.5 million shares of common stock, at $4 per share and $0.01 per warrant. The warrants have a per-share exercise price of $5, are exercisable immediately, and expire five years from the date of issuance. Gross proceeds from the offering are expected to be $12 million. In connection with the offering, more than $34.5 million of the company's debt is being converted and removed from its balance sheet. The company also granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of common stock and/or 225,000 warrants to cover overallotments, if any. The company said its shares will cease trading on the OTC QB and its shares and warrants will begin trading on the NASDAQ Capital Market under the symbols "NWBO" and "NWBOW," respectively.